Analysts Are Bullish on These Healthcare Stocks: Inventiva (IVA), Stereotaxis (STXS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA), Stereotaxis (STXS) and Merck & Company (MRK) with bullish sentiments.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inventiva (IVA)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Inventiva today and set a price target of $26.00. The company’s shares closed last Monday at $5.67.
According to TipRanks.com, Rahimi is a 5-star analyst with an average return of
Currently, the analyst consensus on Inventiva is a Strong Buy with an average price target of $16.20, representing a 195.1% upside. In a report issued on March 25, LifeSci Capital also maintained a Buy rating on the stock with a $14.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Stereotaxis (STXS)
In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Stereotaxis, with a price target of $4.00. The company’s shares closed last Monday at $1.88, close to its 52-week low of $1.66.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
Stereotaxis has an analyst consensus of Strong Buy, with a price target consensus of $4.25, which is an 116.8% upside from current levels. In a report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $4.00 price target.
Merck & Company (MRK)
In a report released today, Trung Huynh from RBC Capital maintained a Buy rating on Merck & Company, with a price target of $142.00. The company’s shares closed last Monday at $120.85.
According to TipRanks.com, Huynh is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck & Company with a $133.44 average price target, representing a 10.8% upside. In a report issued on March 24, BMO Capital also maintained a Buy rating on the stock with a $135.00 price target.
Read More on IVA:
Disclaimer & DisclosureReport an Issue
- Inventiva price target lowered to $15 from $17 at Stifel
- Inventiva Posts Deeper 2025 Loss but Extends Cash Runway Ahead of Key MASH Phase 3 Readout
- Inventiva management to meet with Piper Sandler
- Lanifibranor’s Emerging Role in the MASH Market: Physician Sentiment and Uptake Potential Support a Buy Rating Despite Cash Constraints
- Inventiva initiated with a Buy at Truist
